Zhejiang Xinguang Pharmaceutical Valuation
Is 300519 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 300519 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 300519 (CN¥16.97) wird über unserer Schätzung des Fair Value (CN¥8.7) gehandelt.
Deutlich unter dem Marktwert: 300519 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300519?
Other financial metrics that can be useful for relative valuation.
What is 300519's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥2.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.5x |
Enterprise Value/EBITDA | 16.5x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 300519's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 58.7x | ||
600272 Shanghai Kai Kai Industry | 67.4x | n/a | CN¥2.0b |
301065 Zhejiang Benli Technology | 37.6x | n/a | CN¥2.1b |
002365 Qianjiang Yongan Pharmaceutical | 90.9x | n/a | CN¥2.3b |
301130 Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd | 39.1x | n/a | CN¥2.0b |
300519 Zhejiang Xinguang Pharmaceutical | 26.5x | n/a | CN¥2.1b |
Price-To-Earnings gegen Gleichaltrige: 300519 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (34.8x) mit dem Durchschnitt der anderen Unternehmen (61.3x) vergleicht.
Price to Earnings Ratio vs Industry
How does 300519's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 300519 ist aufgrund seines Price-To-Earnings Verhältnisses (24x) im Vergleich zum CN Pharmaceuticals Branchendurchschnitt (26.6x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 300519's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 26.5x |
Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 300519 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.